



150 W 4th Ave  
Vancouver, BC V5Y 1G6  
**T 1. 604.559.9005**  
**abcellera.com**

## NEWS RELEASE

# AbCellera to Participate at Upcoming Investor Conferences in May and June

2025-04-08

---

VANCOUVER, British Columbia--(BUSINESS WIRE)-- **AbCellera** (Nasdaq: ABCL) today announced that the Company will participate in the following investor conferences:

- Bloom Burton & Co. Healthcare Investor Conference, May 5-6
- Goldman Sachs 46th Annual Global Healthcare conference, June 9-11

Visit **[AbCellera's Investor Relations website](#)** for additional information.

About AbCellera Biologics Inc.

**AbCellera** (Nasdaq: ABCL) discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera's platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the most challenging antibody discovery problems. AbCellera is focused on advancing an internal pipeline of first-in-class and best-in-class programs and collaborating on innovative drug development programs with partners. For more information, please visit **[www.abcellera.com](http://www.abcellera.com)**.

Inquiries

Media: Tiffany Chiu; **[media@abcellera.com](mailto:media@abcellera.com)**, +1(236)521-6774

Business Development: Murray McCutcheon, Ph.D.; [partnering@abcellera.com](mailto:partnering@abcellera.com), +1(604)559-9005  
Investor Relations: Peter Ahn; [ir@abcellera.com](mailto:ir@abcellera.com), +1(778)729-9116

Source: AbCellera Biologics Inc.